cyrilzakka/clinical-trials huggingface dataset:
Physical Evaluation and Quality of Life in the Practice of Fencing in Breast Cancer Support

The data collection of physical evaluations after regular practice of the fencing at patients having surgically been treated for breast cancer highlighted encouraging results both on the functional drawing, and on the improvement of the quality of life.

Recent scientific works show that a regular physical activity decreases the rate of second offense of breast cancer from 20 to 50 % at the women beforehand treated for breast cancer.

The objectives:

* participate as a supplement to the physiotherapist in the mobilization of the operated shoulder
* act in association with the surgical and medical team to release the adhesions superficial
* welcome these women hurt through a participative sports project
* get them a fencing adapted in a friendly atmosphere
* offer them personalized exchanges
* to propose a consequent energy expenditure but according to each and to the context
* have a practice of the operated side
* make them practise a sport with pleasure and without fatal effects

By the practice of the sports activity, investigators wish to help these people upset in their life to find the joy of life, to have projects, to find some pleasure to share moments of user-friendliness. Having led a fight against the disease to help them to lead a new fight of fencer happy to have a practice.

Eligibility Criteria:
Inclusion Criteria:

* patients operated for the breast cancer in the Hospital Rene Dubos
* patients who have sign a consent
* patients having supplied an aptitude certificate in fencing

Exclusion Criteria:

* patients who have a contraindication in the sport
Bleeding Symptoms of Carriers of Hemophilia A and B

To collect and analyze data on female carriers of severe and moderate hemophilia A and B.


Eligibility Criteria:
Inclusion Criteria:

* Female carriers of hemophilia A and B.

Exclusion Criteria:

* Pregnancy.
Clinical Study of Genakumab for Injection in Patients With Acute Gout

To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout

Phase Ib: single arm, open lable, single dose, dose escalation,design. There are 3 dose groups with 10 participant s in each group.

Phase II: randomized, double-blind, active control design.There are 2 dose groups of Genakumab for Injection with 30 participant s in each group and 1 group of Compound Betamethasone Injection with 30 praticipants.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, 18 years ≤ age ≤65 years
* Meeting the American College of Rheumatology (ACR) 2015 preliminary criteria for the classification of acute arthritis of primary gout
* Contraindication, intolerance or lack of efficacy for NSAIDs and/or colchicine
* Body mass index of less than or equal to 45 kg/m2
* Onset of current acute gout flare within 5 days prior to study entry
* Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)
* History of gout flare prior to study entry

Exclusion criteria:

* evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis
* Presence of severe renal function impairment
* Use of specified pain relief medications or biologics ( corticosteroids, narcotics, paracetamol/acetominophen, ibuprofen, colchicine, IL-blocker, and tumor necrosis factor inhibitor) within specified periods prior to study entry
* Live vaccinations within 3 months prior to randomization
* Requirement for administration of antibiotics against latent tuberculosis (TB)
* Any active or recurrent bacterial, fungal, or viral infection
* QTc\>450ms for male, QTc\>470ms for female
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis (EoE) is an inflammatory disorder of the esophagus and is a recognized clinical entity. Symptoms include feeding problems, heartburn, regurgitation, vomiting, abdominal pain and food impaction. The symptoms of EoE may be similar to gastroesophageal reflux disease (GERD) but do not resolve with gastric acid suppression. EoE is defined histologically as the presence of \> 15 intraepithelial eosinophils per high power fields on one or more esophageal biopsy specimens.

This Phase II study is comparing oral budesonide (OBS) to placebo to demonstrate that OBS induces a histologic response and a symptom response using a Dysphagia Symptom Questionnaire over a 16 week course of therapy.

Eligibility Criteria:
Inclusion Criteria:

* Males and Females, age 11-40
* Histologic evidence of EoE
* History of clinical symptoms of EoE including dysphagia
* Willing to continue with dietary, environmental or medical therapy
* Ability to read and understand english
* Written Consent

Exclusion Criteria:

* Any Medical condition that may compromise the safety of the subjects or interfere with the signs and symptoms of EoE
* Use of immunomodulatory therapy
* Current use of swallowed corticosteroids
* Esophageal strictures,varices or upper GI bleed
* Other current diseases of the GI tract
* Current viral infection or immunodeficiency condition
* Pregnancy
* Hypersensitivity to budesonide
* History of non compliance
Internet-based Parent Training for Parents of Children With Externalising Behavior Problems

The study aims to evaluate the efficacy of a 5-week, therapist-guided, internet-delivered parent management training program (BIP SAMBA) targeting children aged 5 - 11 years with externalising behavior problems. The study is a randomised controlled trial with parents of N=30 children participating. The intervention BIP SAMBA is compared with a waitlist control condition. Participants in the control condition will be crossed over to the active treatment after 5 weeks. The primary outcome measure is the Eyberg Child Behavior Inventory (ECBI) at the post treatment (5 weeks after baseline assessment).


Eligibility Criteria:
Inclusion Criteria:

* Being parent of a child between 5 and 11 years
* This child has externalising behavior problems
* The parent has access to the internet
* The parent speaks and write Swedish

Exclusion Criteria:

* The child has an autism diagnosis
* The child has severe conduct problems
* There is domestic violence occurring within the family
* There alcohol or substance abuse occurring within the family
Effects of Post-Isometric Relaxation Technique Vs Soft Tissue Mobilization in Leg Spin Bowlers

Effects of Post-Isometric Relaxation Technique versus Cross Friction Soft Tissue Mobilization in Leg Spin Bowlers with Rotator cuff strain

The existing body of research on Pakistani Cyclists lacks comprehensive investigation into the role of sciatic nerve flossing and active release technique, creating a noticeable gap in understanding the impact of such techniques on the performance, improving flexibility, and overall physical well-being of these athletes. Given the unique physical demands of Cyclists and the potential benefits associated with lower limb muscle strength, a focused exploration in this area is crucial to inform training strategies, enhance athletic performance, and contribute to the holistic development of Pakistani cyclists. To determine the comparative impact of sciatic nerve flossing and active release technique on pain, flexibility, and functionality in the lower limbs of cyclists with sciatica.

Eligibility Criteria:
Inclusion Criteria:

* age 16-30 years
* Symptomatic male bowlers (leg spinners)
* Pain from at least 2 months
* Playing regularly from at least 1 year.
* Difference of ROM as compared to contralateral extremity.

Exclusion Criteria:

* Prior History of shoulder surgery
* Shoulder symptoms requiring medical treatment.
* Cricketers not involved in any other sports.
Rewarding Healthy Behaviors in Pregnancy and Postpartum

This is a single-arm pilot clinical trial with two primary research goals:

1. To test the efficacy of a software's ability to profile eligible individuals who decline participation in a clinical trial ("non-consenters") so that research staff may improve recruitment strategies for subsequent waves of potential participants.
2. To test the feasibility of using the software's contingency management program in a population of pregnant persons in their third trimester of pregnancy.

The first aim of the study is to test the feasibility of using a software program to incentivize pregnant patients to adhere to their prescribed prenatal appointments, postnatal appointment, and healthy behaviors. Participants will receive daily text messages that encourage engagement with health behaviors, and then participants earn points when they attend their scheduled appointments, bring in prescribed monitoring logs, and take their medications as prescribed.

A related aim of the study is to examine the effectiveness of the software system in providing support to researchers in implementing targeted participant recruitment in a manner that is labor-efficient and sustainable. The study will determine the efficacy of the software for (1) using psycho-demographic data to achieve more representative enrollment vis-à-vis target populations and (2) iteratively tailoring outreach materials and communication techniques based on actionable insights about those who participate and those who decline to participate.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant in third trimester of pregnancy
* Between 18 and 52 years of age
* Able to read and speak either English or Spanish
* A patient at Mount Sinai Hospital's OB-Gyn Ambulatory E-Level Clinic

Exclusion Criteria:

* Not pregnant (or no longer pregnant)
* Outside of age range
* Unwilling or unable to complete surveys
* Not a patient at the clinic of interest
Results of the Staged Surgical Approach for Management of Infected Un-united Femoral Shaft Fractures in Adults

Assessment of the efficacy of the multistage technique in the eradication of infection and achieving the union of traumatic infected femoral un-united shaft fractures in adult patients for one year follow up.

All cases will be treated by the induced membrane technique in two stages. In the first stage, thorough debridement of the infected bone and soft tissues and copious lavage will be done.

After radical debridement, primary fixation will be done by either external fixation or antibiotic cement coated internally fixed implants.If there is a bone defect, it will be measured and filled with an antibiotic-impregnated (PMMA) cement spacer. The second stage procedure will be performed 4 to 8 weeks after the first one if soft tissue permits and only if there is no clinical or biochemical evidence of ongoing infection as indicated by normal white blood cell count, C-reactive protein, and erythrocyte sedimentation rate. It includes the exchange of the antibiotic cement spacer by a cancellous bone graft.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 18 and 65 years old.
2. Type 32 according to Arbeitsgemeinschaft für Osteosynthesefragen classification in adults.

Exclusion Criteria:

1. Patients with deficient soft tissue coverage with exposed bone.
2. Patients with reflex sympathetic dystrophy.
3. Spinal injuries associated with neurological complications affecting the lower limbs.
4. Associated head injury affecting the conscious level or the motor power of the injured limb.
5. Associated mutilating limb injury or peripheral amputation.
6. Bone defect more than 6 cm in length.
7. Chronic peripheral ischemia of the limb.
8. Past history of pathological fractures.
The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis

The aim of present study is to examine the effect of low-dose aspirin on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis.

This study prospectively evaluate the impacts of low dose aspirin on survival and cardio-cerebral vascular events in a large cohort of Chinese patients undergoing chronic hemodialysis. Between January 2008, consecutive patients with hemodialysis with aspirin were enrolled.We examine the association of aspirin with all-cause mortality in patients matched by propensity scores using the Kaplan-Meier method and Cox models in "intention-to-treat" analyses.The secondary endpoint was rate of cardio-cerebral events.

Eligibility Criteria:
Inclusion Criteria:

All patients aged 18 to 85, undergoing chronic hemodialysis, who have none of the following exclusion criteria.

Exclusion Criteria:

History of gastric or duodenal ulcers Known allergy to aspirin or other NSAIDs

-
Low Concentration Atropine in the Prevention of Myopia in Children.

This double-blind, randomized controlled clinical study is to evaluate the effectiveness and safety of low concentration atropine in preventing myopia in pre-myopia children, and to explore whether there is a dose effect relationship between different concentrations of atropine in preventing myopia.

The main questions this double-blind, randomized controlled clinical study aims to answer are:

1. To evaluate the effect of low concentration atropine on the incidence of myopia in pre myopia children.
2. To evaluate the effectiveness of low concentration atropine in controlling refractive and axial progression.

Patients are randomly divided into three treatment groups with different atropine concentrations(0.01%, 0.02%, 0.04%) and one control group with atropine dissolvant. Patients are required to use the eye drops every night for one year and record after daily usage.

Eligibility Criteria:
Inclusion Criteria:

1. The age of the screening stage is 6-9 years, both sexes;
2. One eye met the diagnosis of pre-myopia, the spherical equivalent was between -0.50D and +0.75D, the astigmatism was ≥-1.50D, and the best corrected far vision was at least 1.0;
3. At least one of parents suffers from myopia (SE of at least one eye \<=-3.00D);
4. Parents have signed informed consent and agree to participate in screening and follow-up.

Exclusion Criteria:

1. Parents disagree to sign the informed consent;
2. Presence of strabismus, amblyopia, or other ocular abnormalities, or have a history of eye surgery;
3. Presence of other eye or systemic diseases;
4. Allergies to low concentration atropine or sulfuric acid drugs;
5. Histories of using other preventive measures, such as using red light within 6 months or atropine within 1 month;
6. Presence of other situations that the researchers think is not appropriate for patients to be included in the project.
Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa

Hereditary Epidermolysis Bullosa (EBH) are rare dermatologic diseases characterized by cutaneous and mucosa fragility. Oral manifestations of few small cohort have been published. The main objective of this multicentric cohort study first in Europe was to report the oral status of these patients that were consulted in the MRDRC of this disease in Nice (France), Toulouse (France) and Louvain (Belgium). Then a correlation between the oral characteristics and the EBH type will be made, in order to facilitate the management of patient care and the prevention program that can be established to improve their oral health.


Eligibility Criteria:
Inclusion Criteria:

* patient with EBH
* patient consent for examination and use the clinical data for publication purpose

Exclusion Criteria:

-
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

This clinical trial studies giving radiation therapy to the liver in patients with uveal (eye) melanoma who have a specific chromosome loss (monosomy 3) or are DecisionDx Class 2 and therefore more likely to have their disease spread from the eye to the liver. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Early radiation to the liver may reduce the development of tumors in the liver and the overall risk of disease recurrence.

PRIMARY OBJECTIVES:

I. Progression free survival in patients treated with prophylactic hepatic irradiation.

SECONDARY OBJECTIVES:

I. Acute and late term toxicity and overall survival.

OUTLINE:

Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for 10 fractions over approximately 2 weeks.

After completion of study treatment, patients are followed up every 6 months for 5 years.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed uveal melanoma
* Monosomy 3 status (by fluorescent in situ hybridization \[FISH\] or multiplex ligation-dependent probe amplification \[MLPA\]) or DecisionDx class 2
* Tumor thickness \> 3.0 mm
* Has received definitive treatment of uveal melanoma with brachytherapy, proton therapy, stereotactic radiosurgery, or enucleation
* Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG)
* Total bilirubin \< 1.5 mg/dl
* Aspartate transaminase (AST) up to two times normal limit
* Alanine transaminase (ALT) up to two times normal limit
* Creatinine \< 2.0 mg/dl
* Functional left kidney based on computed tomography (CT) imaging
* Positron emission tomography (PET)/CT demonstrating no evidence of metastatic disease
* If a woman is of childbearing potential, a negative serum pregnancy test must be documented; women of childbearing potential must agree to use contraception for the duration of radiation therapy (approximately 3 weeks)
* Understands the trial and procedures and is willing and able to sign the Informed Consent Form

Exclusion Criteria:

* Previous malignancy, other than localized cutaneous squamous cell carcinoma or basal cell carcinoma
* History of prior irradiation to the thorax or abdomen
* Inadequate hepatic or kidney function (as specified above)
* Active peptic ulcer disease
* Upper gastrointestinal bleeding
* Pregnant women or women that refuse to use contraception throughout the entire study period
* Currently receiving chemotherapy
* Refuses to sign the informed consent form
Brown Seaweed as a Breast Cancer Preventive

Japanese postmenopausal women in Japan have about one ninth the rate of American postmenopausal women. Rates of breast cancer double even after just ten years among Japanese women who migrate to the US. Diet is thought to be an important factor, and the investigators were interested in whether dietary seaweed, with and without soy supplements, could influence known biomarkers of breast cancer risk in American women.

33 healthy postmenopausal women were randomized to 6 wk seaweed then 1 wk seaweed plus soy or 6 wk placebo then 1 wk placebo plus soy. Blood and urine samples were collected at the end of each treatment period and analyzed for estrogen, homocysteine, antioxidants, insulin-like growth factors and thyroid hormones. Urine was analyzed for phytoestrogens and iodine.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal (self-reported cessation of menstruation 1 y prior to enrollment)
* If breast cancer survivor, all therapy completed at least 6 months prior to enrollment
* Agreed to eat their normal diet, avoiding seaweeds and phytoestrogen-rich foods,
* Restricting alcoholic intake to #2 drinks (24 g alcohol)/wk -Continuing habitual intake of vitamins, supplements, and medications during the study. -

Exclusion Criteria:

* No allergies to seaweed, soy, shellfish, or iodine
* No current use of tobacco;
* No thyroid dysfunction or treatment within the previous 5 y;
* Negative thyroid peroxidase antibodies as determined by screening;
* No hormone replacement therapy or for breast cancer survivors, no chemotherapy or radiation treatments within the preceding 6 mo
* No history of cancer (other than breast cancer)
* No current gastrointestinal disorders or diabetes; omnivorous eating habits, including meat and dairy products at least twice/wk
* No oral antibiotics, iodine containing medications, or corticosteroids treatment within the previous 3 mo.
Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission

The malaria parasite Plasmodium falciparum remains at sub-patent level throughout the dry season in areas of seasonal malaria transmission. Targeting this parasite reservoir before the transmission season could be a good strategy for malaria control. We are conducting a randomized double blind placebo controlled mass drug administration trial in eight village to clear the dry season low level parasitaemia with an ultimate aim of controlling malaria in eastern Sudan.


Eligibility Criteria:
Inclusion Criteria:

* All residents of the 8 villages

Exclusion Criteria:

* Pregnancy
* History of allergy to sulfa drugs
Study of 18F-FAPI Applied to Gastrointestinal Cancer

Comparison of tumor volume, number, and SUVmax of different primary foci (gastric, duodenal, and colon cancer), lymph node metastases (neck and supraclavicular, mediastinal, abdominal, and pelvic), and distant metastases (brain, lung, liver, bone, pleura, and peritoneum) detected by 18F-FAPI versus 18F-FDG PET/CT imaging.


Eligibility Criteria:
Inclusion Criteria:

* Patients with high clinical suspicion of gastrointestinal tumor and negative 18F-FDG at first diagnosis
* Post-treatment patients with high clinical suspicion of recurrence or metastasis and negative 18F-FDG

Exclusion Criteria:

* The diagnosis can be clarified by 18F-FDG PET/CT examination
* The presence of recurrence or metastasis can be clarified by 18F-FDG PET/CT examination
The Effect of Circuit Exercise Program in Gestational Diabetes

Gestational diabetes (GDM) is defined as 'pregnancy-onset or first noticed glucose intolerance'. The aim of this study is to investigate the effect of circuit exercise program applied in addition to diet therapy on cognitive function, functional exercise capacity, mobility, depression and quality of life in women with gestational diabetes. 60 female participants between the ages of 18-35 who meet the inclusion criteria will be included in the study. Participants will be randomly divided into 2 groups as diet group (n=30) and exercise group (n=30). All participants will receive GDM-specific dietary therapy for 6 weeks. In addition to diet therapy, individuals in the exercise group will be given a circuit exercise program for 6 weeks. Participants will be evaluated for blood values, cognitive status and functionality at the baseline and 6 weeks later.


Eligibility Criteria:
Inclusion Criteria:

* being diagnosed with gestational DM
* being between the ages of 18-35
* being in 24-32 weeks of pregnancy
* being inactive physical activity level - (\<300 MET weeks/day)

Exclusion Criteria:

* Diagnosed with diabetes before pregnancy
* have given birth before
* Multiple Pregnancy (\>2)
* Intrauterine growth restriction
* Preeclampsia
* having high risk of preterm labor and on strict bed rest
* treatment with insulin or oral hypoglycemic agents during pregnancy
* Other significant severe or poorly controlled medical conditions (thyroid disease, cardio-respiratory disorders, ...)
* taking medications that affect cognitive function, including corticosteroids, anti-depressants, or anti-epileptics